Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05725109 · ClinicalTrials.gov registry record
Hepatitis C Diagnosis to Treatment Management
A clinical trial, sponsored by Epividian.
- Completed
- Registry status
- 1,063
- Enrollment target
NCT05725109: Completed study, sponsored by Epividian.
NCT05725109 is a clinical trial that has completed, run by Epividian. The registered enrollment target is 1,063 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05725109 has completed, sponsored by Epividian.
- COMPLETED
- Registry status
- 1,063 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate whether sending alerts to healthcare providers and clinic staff to identify patients with untreated hepatitis C infection can increase the uptake of hepatitis C treatment. A period of time without alerts will be compared to a period of time with alerts.
Primary Outcome
Proportion of patients who are prescribed HCV treatment over follow-up, out of patients with a completed visit over follow-up.
Interventions
- OTHER Standard of Care
- OTHER Hepatitis C Treatment Alerts in CHORUS™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,063 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2023-10-17 |
What the finished NCT05725109 record still lists
NCT05725109 is an observational study that tracks outcomes without assigning an intervention. Its 1,063 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT05725109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05725109 about?
NCT05725109 is a clinical study titled "Hepatitis C Diagnosis to Treatment Management". The objective of this study is to evaluate whether sending alerts to healthcare providers and clinic staff to identify patients with untreated hepatitis C infection can increase the uptake of hepatitis C treatment. A period of time without alerts will be compared to a period of time with alerts.
What is the current status of trial NCT05725109?
This trial is currently completed. The enrollment target is 1,063 participants. The study started on 2023-01-16. Estimated completion is 2023-10-17.
What interventions are being tested in trial NCT05725109?
The interventions under investigation include: Standard of Care (OTHER), Hepatitis C Treatment Alerts in CHORUS™ (OTHER).
Who is sponsoring clinical trial NCT05725109?
This trial is sponsored by Epividian, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04165798 · 1,065 participants
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
- NCT05520762 · 1,060 participants · NA
Hospital Airway Resuscitation Trial
- NCT05911568 · 1,060 participants
Treatment With Endovascular Intervention for STroke Patients With Existing Disability
- NCT07140172 · 1,060 participants · NA
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI